Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Wheatgrass can be grown indoors or outdoors. A common method for sprout production indoors is often on trays in a growth medium such as a potting mix. Leaves are harvested when they develop a "split" as another leaf emerges. These can then be cut off with scissors and allow a second crop of shoots to form. Sometimes a third cutting is possible, but may be tougher and have fewer sugars than the first. Schnabel's research was conducted with wheatgrass grown outdoors in Kansas. His wheatgrass required 200 days of slow growth through the winter and early spring, when it was harvested at the jointing stage. He claimed that at this stage the plant reached its peak nutritional value; after jointing, concentrations of chlorophyll, protein, and vitamins decline sharply. Wheatgrass is harvested, freeze-dried, then sold in tablet and powdered concentrates for human and animal consumption. Indoor-grown wheatgrass is used to make wheatgrass juice powder.
=== Philosophy === While positive psychologists focus on empirical research of specific factors, philosophers place more emphasis on the general nature, overall function, and conceptual foundations of well-being. They explore its essential features by developing and comparing theories of well-being, such as hedonistic theories, desire theories, and objective list theories. Philosophers also investigate the foundational principles of the scientific study of well-being. Considering that well-being has both subjective and evaluative aspects, they seek to determine whether scientific objectivity is possible and to what extent well-being can be quantified and compared between individuals. Some philosophers challenge the concept of well-being, understood as what is ultimately good for someone. For instance, philosopher G. E. Moore (1873–1958) rejects the idea that something can be good relative to a person, asserting instead that all values are impersonal. Another criticism suggests that the concept of well-being is incoherent, arguing that it groups together diverse elements without a shared essence. Despite these criticisms, well-being plays a central role in ethics and value theory. Welfarism is the view that well-being is the only basic source of value. It holds that everything else, like intelligence and health care, is only valuable to the extent that it promotes well-being and reduces ill-being. Pure welfarists argue that the raw sum of everyone's well-being is all that matters.
Diabetes – general term referring to all states characterized by hyperglycemia. It can be of the following types: Type 1 diabetes – autoimmune-mediated destruction of insulin-producing β-cells in the pancreas, resulting in absolute insulin deficiency Type 2 diabetes – either inadequate insulin production by the β-cells or insulin resistance or both because of reasons not completely understood. there is correlation with diet, with sedentary lifestyle, with obesity, with age and with metabolic syndrome. Causality has been demonstrated in multiple model organisms including mice and monkeys; importantly, non-obese people do get Type 2 diabetes due to diet, sedentary lifestyle and unknown risk factors, though this may not be a causal relationship. it is likely that there is genetic susceptibility to develop Type 2 diabetes under certain environmental conditions Other types of impaired glucose tolerance (see Diabetes) Insulinoma – a tumor of beta cells producing excess insulin or reactive hypoglycemia. Metabolic syndrome – a poorly understood condition first called syndrome X by Gerald Reaven. It is not clear whether the syndrome has a single, treatable cause, or is the result of body changes leading to type 2 diabetes. It is characterized by elevated blood pressure, dyslipidemia (disturbances in blood cholesterol forms and other blood lipids), and increased waist circumference (at least in populations in much of the developed world).
The melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in regulating energy homeostasis, appetite, and sexual function. It plays a key role in metabolic processes and it predisposes to certain forms of obesity in humans. MC4R is a receptor that is activated by α-melanocyte-stimulating hormone (α-MSH), influencing energy homeostasis and feeding behavior in the central nervous system. In mouse models, MC4R has been shown to regulate feeding behavior, metabolism, reproductive function, and erectile response.
Sources: en.wikipedia.org
== Mechanical properties == As noted above, the (two-dimensional) density of graphene is 0.762 mg per square meter. Graphene is the strongest material ever tested, with an intrinsic tensile strength of 130 GPa (19,000,000 psi) (with representative engineering tensile strength ~50-60 GPa for stretching large-area freestanding graphene) and a Young's modulus (stiffness) close to 1 TPa (150,000,000 psi). The Nobel announcement illustrated this by saying that a 1 square meter graphene hammock would support a 4 kg cat but would weigh only as much as one of the cat's whiskers, at 0.77 mg (about 0.001% of the weight of 1 m2 of paper). Large-angle bending of graphene monolayers with minimal strain demonstrates its mechanical robustness. Even under extreme deformation, monolayer graphene maintains excellent carrier mobility. The spring constant of suspended graphene sheets has been measured using an atomic force microscope (AFM). Graphene sheets were suspended over SiO2 cavities where an AFM tip was used to apply stress to the sheet to test its mechanical properties. Its spring constant was in the range 1–5 N/m and the stiffness was 0.5 TPa, which differs from that of bulk graphite. These intrinsic properties could lead to applications such as NEMS as pressure sensors and resonators. Due to its large surface energy and out of plane ductility, flat graphene sheets are unstable with respect to scrolling, i.e. bending into a cylindrical shape, which is its lower-energy state.
Birch species are generally small to medium-sized trees or shrubs, mostly of northern temperate and boreal climates. The simple leaves are alternate, singly or doubly serrate, feather-veined, petiolate and stipulate. They often appear in pairs, but these pairs are really borne on spur-like, two-leaved, lateral branchlets. The fruit is a small samara, although the wings may be obscure in some species. They differ from the alders (Alnus, another genus in the family) in that the female catkins are not woody and disintegrate at maturity, falling apart to release the seeds, unlike the woody, cone-like female alder catkins. The bark of all birches is characteristically marked with long, horizontal lenticels, and often separates into thin, papery plates, especially upon the paper birch. Distinctive colors give the common names gray, white, black, silver and yellow birch to different species. The buds, forming early and full-grown by midsummer, are all lateral, without a terminal bud forming; the branch is prolonged by the upper lateral bud. The wood of all the species is close-grained with a satiny texture and capable of taking a fine polish; its fuel value is fair.
He noted that shed scabs (which might be spread via bedsheets or other fomites) often contain “large quantities of virus”, but suggested that the “apparent lack of infectiousness of scab associated virus” might be due to “encapsulation with inspissated pus”. Contaminated needles are the most common fomite that transmits HIV. Fomites from dirty needles also easily spread Hepatitis B.
Changes to the curriculum of American history during the 2010s, especially in left-leaning states, have led to large numbers young Americans having a low opinion of their country and their historical figures. On the other hand, the decline of belief in American exceptionalism is a long-term trend, not unique to this cohort.
Lower levels of the hierarchy are sub-disciplines that do generally not have any role in the title of the university's governance. The proper criteria for organizing knowledge into disciplines is open to debate.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.